Drug
Vorasidenib
Vorasidenib: highest development phase Phase 2, developed by Servier. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vorasidenib NCT07286292 | Phase 2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation |
| Vorasidenib NCT07629089 | Phase 1 | Recurrent Glioma |
| Vorasidenib NCT05484622 | Phase 1 | Astrocytoma |
| Vorasidenib NCT07235774 | Phase 1 | Healthy Adult Female Participants |
Latest
No recent events.
Follow Vorasidenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.